Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06750549 · ClinicalTrials.gov registry record · NA

Mobile Application for Patient Engagement and Physician-Directed Remote Management of Heart Failure

A NA study of Heart Failure, sponsored by University of Michigan.

Active
Registry status
NA
Development phase
130
Enrollment target
3
Study locations

NCT06750549: Active NA study of Heart Failure, sponsored by University of Michigan.

NCT06750549 is a NA study of Heart Failure that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 130 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06750549, a NA study of Heart Failure, is active but no longer recruiting, sponsored by University of Michigan.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
3
Study locations

Study Summary

The ENGAGE-HF mobile application tracks three key features over time: (1) heart failure health status, (2) vital signs (e.g., blood pressure, heart rate) and weight, and (3) the quality of heart failure medication therapy. Helping patients understand how these characteristics interact and change over time may improve their ability to understand and manage heart failure. In this study, the investigators aim to evaluate whether the ENGAGE-HF mobile application, by facilitating the behavior change strategies of self-monitoring and feedback, and a clinician-facing dashboard, improves the optimization of heart failure guideline-directed medical therapies (GDMT) and quality of life. An optional sub-study of cognitive function will invite all eligible participants enrolled in the main study to participate.

Primary Outcome

The primary outcome will be the difference in the medication optimization score at 90 days between the intervention and control group. The MOS is a percent between 0 (least optimized) and 100 (most optimized), which represents the extent of medication optimization that needs to be performed. Inputs for the score include medications, vital signs, and laboratory values, and thus, the score accounts for contraindications to medical therapy titration. The score has been shown to correlate with clini

Conditions Studied

Interventions

  • DEVICE ENGAGE-HF Mobile Application

Study Locations (3)

California

  • Stanford Cardiovascular Clinic - Stanford

Maryland

  • The Johns Hopkins Hospital - Baltimore

Michigan

  • U-M Frankel Cardiovascular Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-02-18
Est. Completion 2026-05-31
Phase NA
University of Michigan

1,327 total trials

What the registry record for NCT06750549 still lists

NCT06750549 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which ENGAGE-HF Mobile Application is the first listed.

NCT06750549 reports a single indexed study location in California, Maryland, Michigan.

Frequently Asked Questions

What is clinical trial NCT06750549 about?

NCT06750549 is a clinical study titled "Mobile Application for Patient Engagement and Physician-Directed Remote Management of Heart Failure". The ENGAGE-HF mobile application tracks three key features over time: (1) heart failure health status, (2) vital signs (e.g., blood pressure, heart rate) and weight, and (3) the quality of heart failure medication therapy. Helping patients understand how these characteristics interact and change ove...

What is the current status of trial NCT06750549?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-02-18. Estimated completion is 2026-05-31.

What conditions does trial NCT06750549 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06750549?

The interventions under investigation include: ENGAGE-HF Mobile Application (DEVICE).

Who is sponsoring clinical trial NCT06750549?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06750549 being conducted?

This trial has 3 study locations across California, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06750549's enrollment target sits among peer trials

130 196th of 397 higher than 200 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

  • NCT02708836 · 130 participants · NA

    Limiting Emergence Phenomena After General Anesthesia With Combined LMA and ETT Airway Management Technique

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06750549, the US trial registry maintained by the National Library of Medicine. NCT06750549 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.